Description
MEGF0444A is an investigational medication currently being studied in clinical trials for metastatic colorectal cancer (CRC). It is being evaluated as a potential treatment option for people whose cancer has spread. In a Phase 2 clinical trial (NCT01399684), MEGF0444A was tested in combination with standard chemotherapy (mFOLFOX-6, which includes 5-Fluorouracil, Leucovorin, and Oxaliplatin) and bevacizumab. The trial compared this combination to a placebo (an inactive substance) combined with the same standard chemotherapy and bevacizumab. The goal was to see if adding MEGF0444A improved outcomes, specifically how long patients lived without their cancer progressing, compared to the standard treatment alone. The trial was randomized, meaning participants were randomly assigned to receive either MEGF0444A or the placebo, and double-blind, meaning neither the participants nor the researchers knew who was receiving which treatment until the end of the study. This helps ensure the results are not biased.
Mechanism of Action
MEGF0444A is being investigated as a potential treatment for colorectal cancer. The specific way it works (its mechanism of action) is not fully detailed in the available trial information. It is being studied in combination with standard chemotherapy and bevacizumab to see if it can improve treatment effectiveness.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.